Oral composition containing sodium citrate

Abstract

The present inventors primarily aimed to provide an oral composition that contains 0.4% by mass or more of sodium citrate while still exhibiting a sufficient minty aroma. [Solution] The present inventors have found that the above problems can be solved by an oral composition containing (A) 0.4 to 2.2% by mass of sodium citrate, (B1) at least one selected from the group consisting of menthone, isomentone, carvone, mentofuran, pulegone, piperitone, viridiflorol, and mintlactone, (B2) at least one cooling agent having a specific structure, (C) at least one selected from the group consisting of caryophyllene, limonene, β-myrcene, α-pinene, and β-pinene, and (D) at least one selected from the group consisting of 1,8-cineole, citral, and linalool.

Description

[Technical Field]

[0001] This disclosure relates to oral compositions containing sodium citrate, etc. [Background technology]

[0002] Oral compositions are generally used to cleanse the oral cavity by removing dirt, to provide a refreshing and invigorating sensation, and to eliminate and prevent bad breath. To achieve these objectives, surfactants are generally incorporated into oral compositions. However, surfactants have a characteristic bitter taste and unpleasant odor (surfactant odor). Oral compositions with a bitter taste and surfactant odor can cause discomfort during and after use (after spitting them out), making them undesirable from a palatability standpoint.

[0003] For this reason, fragrances are usually added to oral compositions, and mint-based fragrances are particularly frequently used. Mint-based fragrances typically contain mint oils such as peppermint oil, spearmint oil, and other mint oils, as well as menthol, carvone, and other ingredients. The minty aroma provided by mint-based fragrances imparts a feeling of coolness and freshness, conveys a sense of cleanliness, and also has the effect of masking unpleasant tastes and odors (base odors) caused by surfactants, etc. Conventionally, techniques for improving the flavor of mint-based fragrances have been studied, and for example, Patent Document 1 proposes a technique for improving the flavor of mint-based fragrances by adding polygodial or polygodial-containing plant extracts. [Prior art documents] [Patent Documents]

[0004] [Patent Document 1] Japanese Patent Application Publication No. 7-145398 [Non-patent literature]

[0005] [Non-Patent Document 1] Mouta LFGL, Marques RS, Koga-Ito CY, Salvador MJ, Giro EMA, Brighenti FL. Cymbopogon citratus Essential Oil Increases the Effect of Digluconate Chlorhexidine on Microcosm Biofilms. Pathogens. 2022;11(10):1067. Published 2022 Sep 20. doi:10.3390 / pathogens11101067 [Overview of the project] [Problems that the invention aims to solve]

[0006] The inventors have discovered that incorporating 0.4% by mass or more of sodium citrate into an oral composition can disperse biofilms in the oral cavity. However, they also discovered a new problem: incorporating 0.4% by mass or more of sodium citrate into an oral composition reduces the intensity of the mint aroma. As mentioned above, the mint aroma provided by mint-based fragrances imparts a feeling of coolness and freshness, conveys a sense of cleanliness, and masks the odor of the base ingredient. Therefore, the inventors' main objective was to provide an oral composition that contains 0.4% by mass or more of sodium citrate while still providing a sufficient mint aroma. [Means for solving the problem]

[0007] The inventors of this invention have found that (A) sodium citrate 0.4 to 2.2% by mass, (B1) At least one selected from the group consisting of menthone, isomentone, carvone, menthofran, pulegone, piperitone, viridiflorol, and mintlactone. (B2) A cooling agent having at least one specific structure, (C) At least one selected from the group consisting of caryophyllene, limonene, β-myrcene, α-pinene, and β-pinene, (D) At least one selected from the group consisting of 1,8-cineole, citral, and linalool It has been found that the above problems can be solved by an oral composition containing the same, and further improvements have been made.

[0008] This disclosure includes, for example, the subject matter described in the following items. Item 1. (A) 0.4 to 2.2% by mass of sodium citrate, (B1) At least one selected from the group consisting of menthone, isomenthone, carvone, menthofuran, pulegone, piperitone, viridiflorol, and mintlactone, (B2) General formula (I): [Chemical formula] (In the formula, R , represents an arbitrary group, and R 2 represents a hydrogen atom or an arbitrary group), and General formula (II): [Chemical formula] (In the formula, R 3 represents an arbitrary group) a compound represented by At least one cooling agent selected from the group consisting of (C) At least one selected from the group consisting of caryophyllene, limonene, β-myrcene, α-pinene, and β-pinene, and (D) At least one selected from the group consisting of 1,8-cineole, citral, and linalool <000011​​​​​​​​​​​​​​​​The oral composition according to any one of items 1 to 3, wherein the total content of the component (B1) and the component (B2) is 0.1 to 3 parts by mass with respect to 1 part by mass of the content of the component (A). Item 5. The oral composition according to any one of items 1 to 4, wherein the component (B2) has at least one functional group selected from the group consisting of carboxy, carboxamide, ketal, ketone, ester, ether, and alcohol. Item 6. The component (B2) is a general formula (I):

Chemical formula

Chemical formula

Chemical formula

Chemical formula

[0009] According to this disclosure, an oral composition containing 0.4% by mass or more of sodium citrate while having a sufficient mint aroma can be provided. As described above, by including 0.4% by mass or more of sodium citrate in the oral composition, biofilms in the oral cavity can be dispersed. Furthermore, the mint aroma can provide a refreshing and invigorating feeling, create a sense of cleanliness, and mask the base odor. In other words, according to the technology of this disclosure, an oral composition that achieves both biofilm dispersion and palatability can be provided. [Modes for carrying out the invention]

[0010] The embodiments included in this disclosure will be described in more detail below. This disclosure preferably includes, but is not limited to, oral compositions containing sodium citrate, methods for improving the mint aroma of oral compositions containing sodium citrate, and so on. This disclosure includes everything disclosed herein and recognizable to those skilled in the art.

[0011] The oral compositions included in this disclosure are: (A) Sodium citrate 0.4-2.2% by mass, (B1) At least one selected from the group consisting of menthone, isomentone, carvone, menthofran, pulegone, piperitone, viridiflorol, and mintlactone. (B2) General formula (I): [ka] (In the formula, R 1 represents any group, R 2 Compounds represented by (where represents a hydrogen atom or any group), and General formula (II): [ka] (In the formula, R 3 Compounds represented by (where represents any group) At least one cooling agent selected from the group consisting of, (C) At least one selected from the group consisting of caryophyllene, limonene, β-myrcene, α-pinene, and β-pinene, (D) At least one selected from the group consisting of 1,8-cineole, citral, and linalool It contains. Hereinafter, the oral composition included in this disclosure may be referred to as "the oral composition of this disclosure."

[0012] Ingredient (A) Sodium citrate is the sodium salt of citric acid. In this disclosure, sodium citrate may be monosodium citrate, disodium citrate, or trisodium citrate, with trisodium citrate being preferred.

[0013] The compositions of this disclosure contain 0.4 to 2.2% by mass of sodium citrate relative to the total composition. The upper or lower limits of the above range may be 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, or 2.2% by mass. The compositions of this disclosure preferably contain 0.4 to 2.0% by mass of sodium citrate relative to the total composition, more preferably 0.4 to 1.8% by mass, even more preferably 0.4 to 1.5% by mass, and particularly preferably 0.6 to 1.0% by mass. If the sodium citrate content is less than 0.4% by mass, a sufficient biofilm dispersion effect may not be achieved. On the other hand, if the sodium citrate content is more than 2.2% by mass, a sufficient mint aroma may not be perceived during use.

[0014] Ingredients (B1) Component (B1) is at least one selected from the group consisting of menthone, isomentone, carvone, menthofuran, pulegone, piperitone, viridiflorol, and mintlactone. These components have a minty aroma.

[0015] In the technology of this disclosure, the content of component (B1) is not particularly limited and may be, for example, 0.01 to 1% by mass relative to the whole composition. The upper or lower limits of the range may be 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1% by mass. The content of component (B1) is preferably 0.02 to 0.9% by mass, more preferably 0.05 to 0.8% by mass, even more preferably 0.1 to 0.5% by mass, and particularly preferably 0.15 to 0.3% by mass relative to the whole composition.

[0016] While not particularly limited, the content of component (B1) in the art of this disclosure may be 0.01 to 1 part by mass per 1 part by mass of component (A). The upper or lower limits of the range may be 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1 part by mass. The content of component (B1) is preferably 0.02 to 0.8 parts by mass, more preferably 0.03 to 0.7 parts by mass, even more preferably 0.05 to 0.6 parts by mass, and particularly preferably 0.08 to 0.5 parts by mass per 1 part by mass of component (A).

[0017] Ingredients (B2) Component (B2) is general formula (I): [ka] (In the formula, R 1 represents any group, R 2 Compounds represented by (where represents a hydrogen atom or any group), and General formula (II): [ka] (In the formula, R 3 Compounds represented by (where represents any group) It is at least one cooling agent selected from the group consisting of the following:

[0018] While not particularly limited, component (B2) preferably has at least one functional group selected from the group consisting of carboxy, carboxamide, ketal, ketone, ester, ether, and alcohol.

[0019] There are no particular restrictions, but R 1 is, -(CH2) n -OH, -O-(CH2) n -CH(OH)-(CH2) m-OH(n and m are integers 0 to 5, preferably 0 to 3, more preferably 0 to 2, independently of each other), general formula (III): [ka] [In the formula, R 4 C1-C5 (preferably C1-C3) alkyl group, -(CH2) n -C(=O)-O-(CH2) m H, -(CH2) n -CH(OH)-R 5 , or -(CH2) n -R 5 And, R 5 This is an alkoxy group having 1 to 3 carbon atoms or -(CH2) m A six-membered aryl group or heteroaryl group which may be substituted with -CN, A base represented by the general formula (IV), where n and m are independent integers from 0 to 5, preferably from 0 to 3, more preferably from 0 to 2: [ka] [In the formula, R 6 [The alkyl group is a branched alkyl group having 1 to 5 carbon atoms (preferably 1 to 3), and the alkyl group may optionally have 1 to 3 hydrogen atoms (preferably 1) substituted with hydroxyl groups.] It is preferable that the group is represented by . In this case, R 2 It is preferable that it is a hydrogen atom.

[0020] There are no particular restrictions, but R 3 This is a group having a structure in which one hydrogen atom is substituted for a hydroxyl group from an alkyl group which may have 2 to 5 carbon atoms (preferably 3 or 4 carbon atoms) and may be branched, or -C(=CH2)-(CH2) p It is preferable that the base be represented by H (where p is an integer between 1 and 3).

[0021] Particularly preferred is component (B2) to be at least one selected from the components shown below.

[0022] [Table 1]

[0023] [Table 2]

[0024] [Table 3]

[0025] [Table 4]

[0026] [Table 5]

[0027] In the technology of this disclosure, the content of component (B2) is not particularly limited and may be, for example, 0.01 to 1% by mass relative to the whole composition. The upper or lower limits of the range may be 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1% by mass. The content of component (B2) is preferably 0.02 to 0.9% by mass, more preferably 0.05 to 0.8% by mass, even more preferably 0.1 to 0.5% by mass, and particularly preferably 0.2 to 0.4% by mass relative to the whole composition.

[0028] While not particularly limited, the content of component (B2) in the art of this disclosure may be 0.01 to 1.5 parts by mass per 1 part by mass of component (A). The upper or lower limits of the range may be 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.1, 1.2, 1.3, 1.4, or 1.5 parts by mass. The content of component (B2) is preferably 0.05 to 1.4 parts by mass, more preferably 0.08 to 1.2 parts by mass, even more preferably 0.1 to 1 part by mass, and particularly preferably 0.15 to 0.9 parts by mass, per 1 part by mass of component (A).

[0029] While not particularly limited, the content of component (B2) in the art of this disclosure may be 0.1 to 5 parts by mass per 1 part by mass of component (B1). The upper or lower limits of the range may be 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.5, 4, 4.5, or 5 parts by mass. The content of component (B2) is preferably 0.2 to 4 parts by mass, more preferably 0.3 to 3 parts by mass, even more preferably 0.5 to 2.5 parts by mass, and particularly preferably 0.8 to 2.2 parts by mass, per 1 part by mass of component (B1).

[0030] While not particularly limited, the total content of component (B1) and component (B2) in the art of this disclosure may be 0.05 to 5 parts by mass per 1 part by mass of component (A). The upper or lower limits of the range are 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.05, 1.1, 1.15, The amounts may be 1.2, 1.25, 1.3, 1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.5, 4, 4.5, or 5 parts by mass. The total content of component (B1) and component (B2) is preferably 0.08 to 4 parts by mass, more preferably 0.1 to 3 parts by mass, even more preferably 0.15 to 2 parts by mass, and particularly preferably 0.2 to 1.5 parts by mass, per 1 part by mass of component (A).

[0031] Furthermore, some plants of the genus Mentha in the Lamiaceae family contain component (B1) and / or component (B2). For example, essential oil derived from peppermint (peppermint oil) contains component (B1) menthone, isomentone, mentofuran, pulegone, viridiflorol, and mintlactone, as well as component (B2) menthol and menthyl acetate. Essential oil derived from spearmint (spearmint oil) contains component (B1) carvone. Essential oil derived from peppermint (menthol oil) contains component (B1) menthone, isomentone, pulegone, and piperitone, as well as component (B2) menthol, menthyl acetate, and isopulegol. Therefore, in the technology of this disclosure, extracts and essential oils derived from plants of the genus Mentha in the Lamiaceae family may be used individually or in combination of two or more.

[0032] While not particularly limited, the oral compositions of this disclosure preferably contain at least menthone and / or carvone as component (B1) and at least menthol and / or menthyl acetate as component (B2). More preferably, the oral compositions of this disclosure contain at least menthone as component (B1) and at least menthol as component (B2).

[0033] Ingredients (C) Component (C) is at least one selected from the group consisting of caryophyllene, limonene, β-myrcene, α-pinene, and β-pinene. All components (C) are terpene hydrocarbons.

[0034] In the technology of this disclosure, the content of component (C) is not particularly limited and may be, for example, 0.00001 to 0.1% by mass relative to the whole composition. The upper or lower limits of the range are 0.00001, 0.00005, 0.0001, 0.0005, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.02, 0.021, 0.022, 0.023, 0.024, 0. It may be 0.25, 0.026, 0.027, 0.028, 0.029, 0.03, 0.031, 0.032, 0.033, 0.034, 0.035, 0.036, 0.037, 0.038, 0.039, 0.04, 0.041, 0.042, 0.043, 0.044, 0.045, 0.046, 0.047, 0.048, 0.049, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1 mass%. The content of component (C) is preferably 0.00005 to 0.09% by mass of the whole composition, more preferably 0.0001 to 0.08% by mass, even more preferably 0.001 to 0.05% by mass, and particularly preferably 0.005 to 0.03% by mass.

[0035] While not particularly limited, the content of component (C) in the art of this disclosure may be 0.00001 to 0.1 parts by mass per 1 part by mass of component (A). The upper or lower limits of the range are 0.00001, 0.00005, 0.0001, 0.0005, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.02, 0.021, 0.022, 0.023, 0.024, 0. It may be 0.25, 0.026, 0.027, 0.028, 0.029, 0.03, 0.031, 0.032, 0.033, 0.034, 0.035, 0.036, 0.037, 0.038, 0.039, 0.04, 0.041, 0.042, 0.043, 0.044, 0.045, 0.046, 0.047, 0.048, 0.049, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1 parts by mass. The content of component (C) is preferably 0.00005 to 0.09 parts by mass, more preferably 0.0001 to 0.08 parts by mass, even more preferably 0.001 to 0.05 parts by mass, and particularly preferably 0.005 to 0.04 parts by mass, per 1 part by mass of component (A).

[0036] Ingredients (D) Component (D) is at least one selected from the group consisting of 1,8-cineole, citral, and linalool. All of component (D) are oxygen-containing terpene compounds. Citral is a general term for geranial and neral, which are a pair of cis-trans isomers.

[0037] In the technology of this disclosure, the content of component (D) is not particularly limited and may be, for example, 0.0001 to 0.5% by mass of the whole composition. The upper or lower limits of the range are 0.0001, 0.0005, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.02, 0.021, 0.022, 0.023, 0.024, 0.025, 0.026, 0.027, 0.028, 0.02 The amounts may be 9, 0.03, 0.031, 0.032, 0.033, 0.034, 0.035, 0.036, 0.037, 0.038, 0.039, 0.04, 0.041, 0.042, 0.043, 0.044, 0.045, 0.046, 0.047, 0.048, 0.049, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, or 0.5% by mass. The content of component (D) is preferably 0.0005 to 0.4% by mass, more preferably 0.001 to 0.3% by mass, even more preferably 0.005 to 0.2% by mass, and particularly preferably 0.01 to 0.15% by mass, relative to the total composition.

[0038] While not particularly limited, the content of component (D) in the art of this disclosure may be 0.0001 to 0.5 parts by mass per 1 part by mass of component (A). The upper or lower limits of the range are 0.0001, 0.0005, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.02, 0.021, 0.022, 0.023, 0.024, 0.025, 0.026, 0.027, 0.028, 0.02 It may be 9, 0.03, 0.031, 0.032, 0.033, 0.034, 0.035, 0.036, 0.037, 0.038, 0.039, 0.04, 0.041, 0.042, 0.043, 0.044, 0.045, 0.046, 0.047, 0.048, 0.049, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, or 0.5 parts by mass. The content of component (D) is preferably 0.0005 to 0.4 parts by mass, more preferably 0.001 to 0.3 parts by mass, even more preferably 0.005 to 0.2 parts by mass, and particularly preferably 0.01 to 0.15 parts by mass, per 1 part by mass of component (A).

[0039] Ingredients (E) While not particularly limited, the compositions of this disclosure preferably further contain component (E): glycyrrhizic acid and / or a salt thereof. When the compositions of this disclosure contain component (E), the mint aroma can be improved more effectively. As will be shown in later examples, component (E) alone does not have a significant mint aroma improving effect, but when combined with components (B1), (B2), (C), and (D), it can synergistically improve the mint aroma. The salt of glycyrrhizic acid is not particularly limited as long as it is a chemically possible salt, for example, sodium salt, potassium salt, ammonium salt, etc. In the art of this disclosure, component (E) is preferably glycyrrhizic acid and / or a potassium salt of glycyrrhizic acid, and is particularly preferably dipotassium glycyrrhizate.

[0040] If the composition of this disclosure contains component (E), its content is not particularly limited and may be, for example, 0.001 to 0.1% by mass of the whole composition. The upper or lower limits of the range are 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.02, 0.021, 0.022, 0.023, 0.024, 0.025, 0.026, 0.027 , 0.028, 0.029, 0.03, 0.031, 0.032, 0.033, 0.034, 0.035, 0.036, 0.037, 0.038, 0.039, 0.04, 0.041, 0.042, 0.043, 0.044, 0.045, 0.046, 0.047, 0.048, 0.049, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1% by mass. If the composition of this disclosure contains component (E), its content is preferably 0.005 to 0.08% by mass, more preferably 0.008 to 0.06% by mass, even more preferably 0.005 to 0.05% by mass, and particularly preferably 0.01 to 0.04% by mass, relative to the whole composition.

[0041] While not particularly limited, the content of component (E) in the art of this disclosure may be 0.001 to 0.1 parts by mass per 1 part by mass of component (A). The upper or lower limits of the range are 0.01, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.02, 0.021, 0.022, 0.023, 0.024, 0.025, 0.026, 0.027, 0.028, 0.029, 0.03, 0.031, 0.0 The amount may be 32, 0.033, 0.034, 0.035, 0.036, 0.037, 0.038, 0.039, 0.04, 0.041, 0.042, 0.043, 0.044, 0.045, 0.046, 0.047, 0.048, 0.049, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1 parts by mass. The content of component (E) is preferably 0.002 to 0.08 parts by mass, more preferably 0.005 to 0.07 parts by mass, even more preferably 0.008 to 0.05 parts by mass, and particularly preferably 0.01 to 0.03 parts by mass, per 1 part by mass of component (A).

[0042] Other optional components The oral compositions of this disclosure may further contain, in addition to the above-mentioned components (A), (B1), (B2), (C), and (D), and optionally component (E), any other components that can be incorporated into the oral composition, such as surfactants, flavoring agents other than components (B1), (B2), (C), and (D), sweeteners, humectants, binders, preservatives, colorants, pH adjusters other than component (A), abrasives, and pharmaceutically active ingredients, either individually or in combination of two or more.

[0043] For example, at least one surfactant selected from the group consisting of nonionic surfactants, anionic surfactants, and amphoteric surfactants can be incorporated.

[0044] Specifically, examples of nonionic surfactants include polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, polyoxyalkylene glycerin fatty acid esters, polyoxyalkylene fatty acid amides, polyoxyalkylene glycol fatty acid esters, polyoxyalkylene castor oil derivatives, polyoxyalkylene hydrogenated castor oil, polyoxyalkylene hydrogenated castor oil derivatives, polyglycerin fatty acid esters, monoglycerin fatty acid esters, sorbitan fatty acid esters, sorbitan fatty acid esters, alkyl glycol fatty acid esters, alkyl polyglycosides, sugar fatty acid esters (sucrose fatty acid esters, maltose fatty acid esters, lactose fatty acid esters, etc.), fatty acid alkanolamides, and diethyl sebacate. When a nonionic surfactant has a polyoxyalkylene moiety, it is preferable that the polyoxyalkylene moiety is a polyoxyethylene moiety.

[0045] Examples of anionic surfactants include sulfate ester salts such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate; sulfosuccinate salts such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; acyl amino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methylalanine; and acyl methyl taurate salts such as sodium cocoyl methyl taurate.

[0046] Examples of amphoteric surfactants include betaine-type surfactants such as lauryldimethylaminoacetic acid betaine and coconut oil fatty acid amidopropyldimethylaminoacetic acid betaine; and imidazoline-type surfactants such as N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine sodium. Surfactants can be formulated individually or in combination of two or more.

[0047] Examples of sweeteners that can be used include sodium saccharin, potassium acesulfamethamate, stevia, stevioside, neohesperidyl dihydrochalcone, perillartin, thaumatin, aspartylphenylalanyl methyl ester, and p-methoxycinnamic aldehyde. The sweeteners can be used individually or in combination of two or more.

[0048] As a wetting agent, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol, etc., can be used individually or in combination of two or more.

[0049] Examples of binders include cellulose derivatives such as sodium carboxymethylcellulose, carboxymethyl ethylcellulose salt, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, crystalline cellulose, and crystalline cellulose-carmellose sodium; microbially produced polymers such as xanthan gum; natural polymers or natural rubbers such as tragacanth gum, karaya gum, arabic gum, carrageenan, dextrin, agar, pectin, pullulan, gellan gum, locust bean gum, and sodium alginate; synthetic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl methyl ether, and sodium polyacrylate; inorganic binders such as thickening silica and bee gum; and cationic binders such as O-[2-hydroxy-3-(trimethylammonio)propyl]hydroxyethylcellulose chloride. Binders can be used individually or in combination of two or more.

[0050] As preservatives, parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben, as well as benzoic acid, sodium benzoate, phenoxyethanol, and alkyldiaminoethylglycine hydrochloride can be included. Preservatives can be used individually or in combination of two or more.

[0051] As colorants, legally approved pigments such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3, mineral pigments such as ultramarine, enhanced ultramarine, and navy blue, and titanium dioxide may be included. The colorants may be used individually or in combination of two or more.

[0052] Other pH adjusting agents besides component (A) may include citric acid, phosphoric acid, malic acid, pyrophosphate, lactic acid, tartaric acid, glycerophosphate, acetic acid, nitric acid, or chemically possible salts thereof, as well as sodium hydroxide, potassium hydroxide, etc. The pH adjusting agents may be added individually or in combination of two or more to ensure that the pH of the oral composition is in the range of 4 to 8, preferably 5 to 7. The amount of pH adjusting agent added may be, for example, 0.01 to 2% by mass.

[0053] Examples of abrasives include calcium carbonate, magnesium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium phosphate, silica, zeolite, sodium metaphosphate, aluminum hydroxide, magnesium hydroxide, calcium pyrophosphate, red iron oxide, calcium sulfate, and anhydrous silicic acid. Abrasives can be used individually or in combination of two or more.

[0054] The oral compositions disclosed herein further include, as active ingredients, amphoteric bactericides such as dodecyldiaminoethylglycine, nonionic bactericides such as isopropylmethylphenol and triclosan, anionic bactericides such as sodium lauroyl sarcosinate, cationic bactericides such as cetylpyridinium chloride, chlorhexidine hydrochloride, benzalkonium chloride, and benzethonium chloride, enzymes such as dextranase, amylase, protease, mutanase, lysozyme, and lytic enzymes (Litec enzyme), and alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate. Fluorides such as phosphate, sodium fluoride, and stannous fluoride, alkali metal salts of dl-α-tocopherol 2-L-ascorbic acid phosphate, tranexamic acid, epsilon-aminocaproic acid, aluminum chlorohydroxyl allantoin, allantoin, dihydrocholesterol, glycyrrhetinic acid, hinokitiol, sodium copper chlorophyllin, glycerophosphate, chlorophyll, sodium chloride, caropeptide, pyridoxine hydrochloride, carbazochrome, potassium nitrate, and palatinite can be formulated individually or in combination of two or more.

[0055] Furthermore, water, alcohols, silicones, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, Plastibase, etc., can be added as bases. These can be formulated individually or in combination of two or more.

[0056] Oral compositions of the present disclosure The dosage form of the oral composition of this disclosure is not particularly limited and may be a solid composition, a semi-solid composition, a liquid composition, etc. More specifically, it may be in the form of an ointment, paste, paste, gel, liquid, spray, mouthwash, liquid toothpaste, toothpaste, gum, tablet, drop, etc., and among these, ointments, pastes, gels, liquids, mouthwashes, liquid toothpastes, and toothpastes are preferred.

[0057] The method for preparing the oral compositions of this disclosure is not particularly limited as long as the effects of this disclosure are achieved. For example, they can be prepared in accordance with methods known in the art. More specifically, they can be prepared by appropriately mixing components (A), (B1), (B2), (C), (D), and optionally component (E), and other components, etc.

[0058] Purpose Biofilms are polymeric film-like structures that form on the surface of teeth and gums, consisting of bacteria, their remains, polysaccharides secreted by bacteria, and proteins. Biofilms in the oral cavity are known to cause tooth decay (dental caries), periodontal diseases such as gingivitis and periodontitis, and bad breath.

[0059] As will be shown in later examples, the inventors have found that by incorporating 0.4% by mass or more of sodium citrate into an oral composition, biofilms in the oral cavity can be dispersed. Therefore, the oral composition of this disclosure containing 0.4% by mass or more of sodium citrate can be preferably used for applications such as oral biofilm dispersion, oral biofilm removal, caries inhibition, periodontal disease prevention, and bad breath suppression.

[0060] Furthermore, as will be shown in later examples, the inventors discovered a new problem: the mint aroma was reduced when 0.4% by mass or more of sodium citrate was incorporated into the oral composition. To improve the mint aroma, the inventors first increased the content of the mint-flavored component and the cooling agent. However, surprisingly, even with increased content of these components, no significant improvement in the mint aroma was obtained. Therefore, the inventors conducted further investigations and found that by combining 0.4 to 2.2% by mass of sodium citrate with the above components (B1), (B2), (C), and (D), it was possible to achieve both biofilm dispersion and a sufficient mint aroma, which is desirable. Since the mint aroma provides a feeling of coolness and freshness and can be perceived as clean, the composition of this disclosure, which achieves both biofilm dispersion and a sufficient mint aroma, can be particularly preferably used for bad breath suppression.

[0061] Examples of animals to whom the oral compositions of this disclosure are applicable include mammals, including humans (e.g., dogs, cats, mice, rats, sheep, horses, cattle, monkeys, etc.), with humans being particularly preferred. Examples of humans to whom the oral compositions of this disclosure are applicable include people with or suspected of having tooth decay, people who want to prevent the onset of tooth decay, people who want to suppress the progression of tooth decay, people at high risk of tooth decay, people with or suspected of having periodontal disease, people who want to prevent the onset of periodontal disease, people who want to suppress the progression of periodontal disease, people at high risk of periodontal disease (elderly people, smokers, people with high blood sugar levels, etc.), people who want to keep their oral cavity clean, and people who want to prevent and / or improve bad breath.

[0062] Method of Disclosure This disclosure also includes a method for improving the mint aroma in an oral composition by including component (A) sodium citrate in an amount of 0.4 to 2.2% by mass, as well as components (B1), (B2), (C), (D), and optionally component (E). This method may be referred to as "the method of this disclosure" in this disclosure. Matters described in this disclosure relating to the oral composition shall be incorporated into the method of this disclosure.

[0063] Manufacturing method disclosed herein This disclosure also includes a method for producing an oral composition, comprising the step of mixing the above components (A), (B1), (B2), (C), (D), and optionally component (E). This method may be referred to as the "method of production of this disclosure." The matters described herein relating to the oral composition and the method of production of this disclosure shall be incorporated by reference to the method of production of this disclosure.

[0064] In this specification, the term “comprising” includes not only “containing” but also “essentially consisting of” and “consisting of.” Furthermore, this disclosure encompasses all combinations of the constituent elements described herein.

[0065] Furthermore, the various characteristics (properties, structure, numerical values, functions, etc.) described for each embodiment of this disclosure described above may be combined in any way to identify the subject matter covered by this disclosure. In other words, this disclosure covers all subject matter consisting of any combination of the combinable characteristics described herein. [Examples]

[0066] The embodiments of this disclosure will be described in more detail below with examples, but the embodiments of this disclosure are not limited to the examples below.

[0067] Test 1. Biofilm Dispersion Test 1-1. Method 1-1-1. Biofilm formation In a cleanroom, approximately 15 mL of naturally secreted saliva was collected from one healthy subject. The collected saliva was passed through a syringe fitted with a 23G needle five times, and then diluted with 15 mL of phosphate-buffered saline. 0.5 mL of the diluted saliva was added to each 24-well plate, and hydroxyapatite (HA) discs (manufactured by Cosmo Bio) were placed in the plate and immersed for 1 hour. Subsequently, the HA discs were transferred to a 24-well plate containing 1 mL of 2% sucrose-added McBain medium (Non-Patent Literature 1), and cultured under anaerobic conditions at 37°C for 24 hours to form a biofilm on the surface of the HA discs.

[0068] 1-1-2. Preparation of sodium citrate aqueous solution Sodium citrate was dissolved in distilled water to prepare aqueous solutions of sodium citrate with concentrations of 0.1% by mass, 0.2% by mass, 0.4% by mass, 0.6% by mass, 0.8% by mass, and 1.0% by mass.

[0069] 1-1-3. Biofilm Dispersion Test HA discs with biofilm formed on their surface using the method described in 1-1-1 were removed from the culture medium and washed with 1 mL of distilled water. 0.5 mL of sodium citrate aqueous solutions of various concentrations were added to a 24-well plate, the washed HA discs were placed in the plate, and the plate was shaken at 500 rpm for 3 minutes using a plate mixer. The same procedure was also performed, except that 0.5 mL of water was used instead of sodium citrate aqueous solution, to create a negative control (hereinafter also referred to as NC).

[0070] After shaking, the HA disk was removed, washed with 1 mL of distilled water, and then stained in 0.01% crystal violet (CV) solution for 20 minutes. After staining, the HA disk was washed with 1 mL of distilled water and air-dried for 30 minutes to 1 hour until it was visually confirmed to be dry. The air-dried HA disk was then immersed in 0.5 mL of 33% acetic acid solution for 30 minutes to extract the dye. 100 μL of the extract was dispensed into a 96-well plate, and the absorbance at 550 nm was measured using a Cytation 5 spectrophotometer (Bio-Tek). The absorbance was measured for each sample (n=2), and the average value was calculated.

[0071] Furthermore, CV staining stains the biofilm on the HA disk surface. Therefore, a higher absorbance of the extraction solution at 550 nm indicates a greater amount of biofilm remaining on the HA disk surface, while a lower absorbance of the extraction solution at 550 nm indicates a smaller amount of biofilm remaining on the HA disk surface. The biofilm retention rate (%) was calculated using the following formula. Biofilm retention rate (%) = (Average absorbance of sample treated with sodium citrate aqueous solution / Average absorbance of NC) × 100

[0072] 1-2. Results The results are shown in the table below. A lower biofilm retention rate was achieved when treated with an aqueous sodium citrate solution at a concentration of 0.4% by mass or higher. These results suggest that a sodium citrate concentration of 0.4% by mass or higher may exhibit excellent biofilm dispersion properties.

[0073] [Table 6]

[0074] Test 2. Sensory evaluation of oral compositions 2-1. Method 2-1-1. Preparation of mint-based fragrances Mint-based fragrances b-1 to b-5 were prepared according to the compositions shown in the table below. Note that the values ​​in the table represent mass percentages.

[0075] [Table 7]

[0076] 2-1-2. Preparation of oral compositions An oral composition (toothpaste) was prepared by mixing the ingredients shown in the table below. The specific amounts of ingredient (A), mint-based fragrance, and ingredients (C) to (E) are shown in section "2-2. Results".

[0077] [Table 8]

[0078] 2-1-3. Sensory Evaluation For each toothpaste prepared by the method described in 2-1-2, four trained sensory evaluators evaluated the intensity of the mint aroma during brushing, the refreshing aftertaste, and the intensity of the base odor. Each evaluator placed 1 g of toothpaste on a toothbrush and brushed their teeth, making evaluations based on the following criteria.

[0079] 5: I feel it strongly 4: Feel 3: Slightly perceptible 2: I hardly feel anything. 1: I don't feel it at all.

[0080] <Base odor> 5: I don't feel it at all. 4: I hardly feel anything. 3: Slightly perceptible 2: Feel 1: I feel it strongly

[0081] 2-2. Results The average score from four evaluators was calculated for each evaluation item. The results, along with the amounts (mass %) of ingredient (A), mint-based fragrance, and ingredients (C) to (E), are shown in the table below.

[0082] [Table 9]

[0083] [Table 10]

[0084] [Table 11]

[0085] [Table 12]

[0086] As shown in the reference example, when the sodium citrate content is 0.3% by mass, a composition was obtained that exhibited excellent mint aroma and a refreshing aftertaste, with almost no base odor, even without the inclusion of components (C) and (D). However, from the results of Test 1, it is inferred that the reference example with a sodium citrate content of 0.3% by mass does not exhibit a significant biofilm dispersion effect. On the other hand, in Comparative Examples 1 to 10, where the sodium citrate content was 0.4% by mass or more and a biofilm dispersion effect was inferred to be achieved, the evaluation of mint aroma, base odor, and refreshing aftertaste was poor. Comparative Examples 1 to 4 and Comparative Example 7 did not contain components (C) and (D), Comparative Example 5 did not contain component (D), and Comparative Example 6 did not contain component (C). Comparative Example 8 did not contain component (B2), and Comparative Example 9 did not contain component (B1). Comparative Example 10 contains all of components (B1), (B2), (C), and (D), but the content of component (A): sodium citrate is 2.5% by mass.

[0087] A comparison between the reference example and comparative example 1, which had the same composition except for the sodium citrate content, suggested that when the sodium citrate content was 0.4% by mass or more, the mint aroma, base odor, and refreshing aftertaste were significantly worsened. Furthermore, a comparison of the reference example, comparative example 1, and comparative example 2 suggested that the negative effects of containing 0.4% by mass or more of sodium citrate could not be suppressed even by doubling the amounts of components (B1) and (B2).

[0088] On the other hand, in Examples 1 to 12, which contained 0.4% by mass or more of sodium citrate and all of components (B1), (B2), (C), and (D), the evaluation of mint aroma, base odor, and refreshing aftertaste was excellent. A comparison between Example 12 and Comparative Example 10, which had the same composition except for the sodium citrate content, suggested that if the sodium citrate content is less than 2.5% by mass, the negative effects of sodium citrate can be suppressed by components (B1), (B2), (C), and (D).

[0089] Furthermore, in Examples 8-12, which contained ingredient (E): dipotassium glycyrrhizinate, the evaluation of mint aroma, base odor, and refreshing aftertaste was particularly outstanding. From Comparative Example 7, it can be inferred that ingredient (E) alone cannot suppress the negative effects of sodium citrate. Therefore, it is thought that ingredient (E) enhances the effects of ingredients (B1), (B2), (C), and (D) when combined with them.

[0090] Prescription examples [Table 13]

[0091] [Table 14]

[0092] [Table 15]

[0093] [Table 16]

[0094] [Table 17]

[0095] [Table 18]

[0096] [Table 19]

[0097] [Table 20]

[0098] Table 21

[0099] Table 22

Claims

1. (A) Sodium citrate 0.4 to 2.2% by mass, (B1) At least one selected from the group consisting of menthone, isomentone, carvone, menthofuran, pulegone, piperitone, viridiflorol, and mintlactone. (B2) General formula (I): 【Chemistry 1】 (In the formula, R １ represents any group, R ２ Compounds represented by (where represents a hydrogen atom or any group), and General formula (II): 【Chemistry 2】 (In the formula, R ３ Compounds represented by (where represents any group) At least one cooling agent selected from the group consisting of, (C) At least one selected from the group consisting of caryophyllene, limonene, β-myrcene, α-pinene, and β-pinene, (D) At least one selected from the group consisting of 1,8-cineole, citral, and linalool An oral composition containing [the specified ingredient].

2. moreover, (E) Glycyrrhizic acid and / or its salt An oral composition according to claim 1, comprising the above.

3. The oral composition according to claim 2, wherein the content of component (E) is 0.01 to 0.1% by mass.

4. The oral composition according to any one of claims 1 to 3, wherein the total content of component (B1) and component (B2) is 0.1 to 3 parts by mass per 1 part by mass of component (A).

5. The oral composition according to any one of claims 1 to 3, wherein the component (B2) has at least one functional group selected from the group consisting of carboxy, carboxamide, ketal, ketone, ester, ether, and alcohol.

6. The aforementioned component (B2) is general formula (I): 【Transformation 3】 Compounds represented by, and General formula (II): 【Chemistry 4】 Compounds represented by the following formula: 【Transformation 5】 A cooling agent selected from the group consisting of compounds represented by, The aforementioned R １ teeth, -(CH ２ ) ｎ -OH、 -O-(CH ２ ) ｎ -CH(OH)-(CH ２ ) ｍ -OH (n and m are independently integers from 0 to 5). General formula (III): 【Transformation 6】 [In the formula, R ４ is an alkyl group having 1 to 5 carbon atoms, -(CH ２ ) ｎ -C(=O)-O-(CH ２ ) ｍ H, -(CH ２ ) ｎ -CH(OH)-R ５ , or - (CH ２ ) ｎ -R ５ And, R ５ This is an alkoxy group having 1 to 3 carbon atoms or -(CH ２ ) ｍ A six-membered aryl group or heteroaryl group which may be substituted with -CN, A base represented by [where n and m are independent integers from 0 to 5], or General formula (IV): 【Transformation 7】 [In the formula, R ６ [The alkyl group is a branched alkyl group having 1 to 5 carbon atoms, and the alkyl group may have 1 to 3 hydrogen atoms substituted with hydroxyl groups], The aforementioned R ２ is a hydrogen atom, and, The aforementioned R ３ This refers to a group having a structure in which one hydrogen atom is substituted for a hydroxyl group from an alkyl group that may have 2 to 5 carbon atoms and be branched, or -C(=CH ２ )-(CH ２ ) ｐ An oral composition according to any one of claims 1 to 3, wherein the group is represented by H (where p is an integer from 1 to 3).

Images